Korsana Biosciences, Inc. KRSA
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- +322.50%
- 1 year
- +277.87%
Held by funds
5 US ETFs and mutual funds hold KRSA · largest positions
Ownership
- Institutions 91.9%
- Insiders 5.11%
- Public and other holders 3.02%
Top institutional holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fairmount Funds Management LLC | 19.99% | 9,103,729 | 341.94M | Sep 29, 2026 |
| TCG Crossover Management, LLC | 9.99% | 4,549,587 | 170.88M | Sep 29, 2026 |
| Venrock Adviser, LLC | 9.99% | 4,549,585 | 170.88M | Sep 29, 2026 |
| FMR, LLC | 7.03% | 3,201,135 | 120.23M | Sep 29, 2026 |
| JPMORGAN CHASE & CO | 5.90% | 2,687,943 | 100.96M | Sep 29, 2026 |
| FCPM III Services B.V. | 4.81% | 2,192,155 | 82.34M | Sep 29, 2026 |
Top mutual fund holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.79% | 813,163 | 30.54M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.50% | 226,583 | 8.51M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 0.45% | 205,493 | 7.72M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 0.29% | 131,547 | 4.94M | Sep 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.14% | 65,364 | 2.46M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.11% | 51,518 | 1.94M | Sep 29, 2026 |
Included in Plus and up
Sign in to see Institutional ownership
How much funds own from their 13F filings, quarter by quarter, and the largest holders.
Free with an account
Sign in to see Insider activity
Two years of insider buying and selling by month, marked on the price.
Included in Plus and up
Sign in to see Congress trading
Every stock trade disclosed by members of the US Senate and House.
Leadership team
Who runs KRSA, and what each was last paid
Jonathan Violin, President, CEO, Secretary & DirectorAverage age 50
| Name | Title | Pay | Age |
|---|---|---|---|
| Jonathan Violin | President, CEO, Secretary & Director | — | 51 |
| Mark Joseph Vignola | Chief Financial Officer | $355K | 48 |
| Kyle Breidenstine | Senior Vice President of Finance & Treasurer | — | — |
| Madelyn Demsky Zeylikman | General Counsel | — | 52 |
| Gan Wei | Chief Technical Officer | — | — |
| Matthew Leoni | Chief Medical Officer | — | — |
Pay is the latest total FMP has for each person (salary, bonus, stock and other awards) and can lag the newest proxy statement. Source: Financial Modeling Prep, from the company’s SEC filings.
Free with an account
Sign in to see CEO compensation
What the chief executive was paid each year, by salary, bonus and stock, beside the company's earnings.
Free with an account
Sign in to see Board of directors
Who sits on the board, who chairs it, and how long each director has served.
Insiders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHICKO RHONDA M. CPA | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 25,018 |
| GRAUL REGINA MARGARET | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 107,523 |
| HECHT PETER M | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jul 15, 2026 | 910,312 |
| HIGGINS MICHAEL J | Director | Stock Award(Grant) | Mar 24, 2025 | 30,740 |
| SLATE PATH CAPITAL LP | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 20, 2024 | 0 |
